Galapagos NV Company Profile (NASDAQ:GLPG)

About Galapagos NV (NASDAQ:GLPG)

Galapagos NV logoGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GLPG
  • CUSIP: N/A
  • Web: www.glpg.com
Capitalization:
  • Market Cap: $3.83 billion
  • Outstanding Shares: 46,256,000
Average Prices:
  • 50 Day Moving Avg: $87.04
  • 200 Day Moving Avg: $73.11
  • 52 Week Range: $49.43 - $94.88
P/E:
  • Trailing P/E Ratio: 827.90
  • Foreward P/E Ratio: -44.04
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $192.7 million
  • Price / Sales: 19.87
  • Book Value: $17.64 per share
  • Price / Book: 4.69
Profitability:
  • EBIDTA: ($2,080,000.00)
  • Net Margins: -67.15%
  • Return on Equity: -8.23%
  • Return on Assets: -5.78%
Debt:
  • Current Ratio: 7.42%
  • Quick Ratio: 7.42%
Misc:
  • Average Volume: 188,476 shs.
  • Beta: 1.85
  • Short Ratio: 2.36
 

Frequently Asked Questions for Galapagos NV (NASDAQ:GLPG)

What is Galapagos NV's stock symbol?

Galapagos NV trades on the NASDAQ under the ticker symbol "GLPG."

Where is Galapagos NV's stock going? Where will Galapagos NV's stock price be in 2017?

7 brokerages have issued 1 year price targets for Galapagos NV's stock. Their predictions range from $48.00 to $87.00. On average, they expect Galapagos NV's share price to reach $70.50 in the next year. View Analyst Ratings for Galapagos NV.

What are analysts saying about Galapagos NV stock?

Here are some recent quotes from research analysts about Galapagos NV stock:

  • 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (4/24/2017)
  • 2. Instinet analysts commented, "We are initiating coverage on Galapagos (GLPG) with a buy rating and $87 target price. We believe the company's rapidly advancing cystic fibrosis (CF) pipeline, partnered with AbbVie, will drive shares higher in the next 12 months. We also anticipate an increasing focus on filgotinib's opportunity in Crohn's disease, and ulcerative colitis (UC) in Phase 3 trials, may lead to upside in shares over the next 12-months. In our view, the current valuation is predominantly supported primarily by the blockbuster opportunity for the company's lead oral JAK1 inhibitor, filgotinib (partnered with Gilead), for the treatment of rheumatoid arthritis." (3/1/2017)
  • 3. Cowen and Company analysts commented, "Galapagos reported positive data from the SAPHIRA1 trial of GLPG1837 in G551D CF." (12/23/2016)

Are investors shorting Galapagos NV?

Galapagos NV saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 373,445 shares, an increase of 16.2% from the April 13th total of 321,454 shares. Based on an average daily volume of 486,165 shares, the short-interest ratio is currently 0.8 days.

Who are some of Galapagos NV's key competitors?

When did Galapagos NV IPO?

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who owns Galapagos NV stock?

Galapagos NV's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (10.00%), EcoR1 Capital LLC (1.19%), Wellington Management Group LLP (0.99%), Renaissance Technologies LLC (0.67%), Perceptive Advisors LLC (0.59%) and Goldman Sachs Group Inc. (0.43%). View Institutional Ownership Trends for Galapagos NV.

Who sold Galapagos NV stock? Who is selling Galapagos NV stock?

Galapagos NV's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Perceptive Advisors LLC, Citadel Advisors LLC, Bank of New York Mellon Corp, Peregrine Capital Management LLC, Morgan Stanley, EcoR1 Capital LLC and P.A.W. Capital Corp. View Insider Buying and Selling for Galapagos NV.

Who bought Galapagos NV stock? Who is buying Galapagos NV stock?

Galapagos NV's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Clough Capital Partners L P, Wellington Management Group LLP, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Driehaus Capital Management LLC, Bogle Investment Management L P DE and Oxford Asset Management. View Insider Buying and Selling for Galapagos NV.

How do I buy Galapagos NV stock?

Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Galapagos NV stock cost?

One share of Galapagos NV stock can currently be purchased for approximately $82.79.

Analyst Ratings

Consensus Ratings for Galapagos NV (NASDAQ:GLPG) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $70.50 (14.84% downside)

Analysts' Ratings History for Galapagos NV (NASDAQ:GLPG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017Stifel NicolausBoost Price TargetHold$65.00 -> $83.00LowView Rating Details
4/24/2017Janney Montgomery ScottDowngradeBuy -> SellHighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/23/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
10/18/2016Goldman Sachs Group IncUpgradeNeutral -> BuyN/AView Rating Details
6/17/2016Credit Suisse Group AGReiterated RatingHold$48.00N/AView Rating Details
5/2/2016Morgan StanleyReiterated RatingBuy$89.00N/AView Rating Details
12/17/2015Bryan, Garnier & CoBoost Price TargetBuy$52.00 -> $64.00N/AView Rating Details
12/8/2015KBC SecuritiesUpgradeBuyN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Galapagos NV (NASDAQ:GLPG)
Earnings by Quarter for Galapagos NV (NASDAQ:GLPG)
Earnings History by Quarter for Galapagos NV (NASDAQ:GLPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2015Q3($0.80)$11.46 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galapagos NV (NASDAQ:GLPG)
Current Year EPS Consensus Estimate: $-2.50 EPS
Next Year EPS Consensus Estimate: $-1.88 EPS

Dividends

Dividend History for Galapagos NV (NASDAQ:GLPG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galapagos NV (NASDAQ:GLPG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Galapagos NV (NASDAQ:GLPG)
Latest Headlines for Galapagos NV (NASDAQ:GLPG)
Source:
DateHeadline
americanbankingnews.com logoGalapagos NV (GLPG) Upgraded to "C" by TheStreet
www.americanbankingnews.com - May 19 at 2:50 PM
finanznachrichten.de logoGalapagos NV: Galapagos creates new warrant plan
www.finanznachrichten.de - May 17 at 10:27 PM
americanbankingnews.com logoGalapagos NV (GLPG) Expected to Announce Quarterly Sales of $26.5 Million
www.americanbankingnews.com - May 17 at 10:54 AM
feeds.benzinga.com logoSeven abstracts on filgotinib accepted by EULAR 2017
feeds.benzinga.com - May 15 at 4:46 PM
americanbankingnews.com logoZacks: Brokerages Expect Galapagos NV (GLPG) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - May 15 at 12:30 PM
americanbankingnews.com logoShort Interest in Galapagos NV (GLPG) Rises By 16.2%
www.americanbankingnews.com - May 13 at 9:20 AM
finanznachrichten.de logoGalapagos NV: Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017
www.finanznachrichten.de - May 8 at 5:13 PM
americanbankingnews.com logoGalapagos NV (GLPG) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 8 at 12:48 PM
feeds.benzinga.com logoGalapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017
feeds.benzinga.com - May 7 at 12:04 PM
americanbankingnews.com logoFY2017 EPS Estimates for Galapagos NV (GLPG) Reduced by Jefferies Group
www.americanbankingnews.com - May 4 at 3:34 PM
finance.yahoo.com logoGalapagos NV :GLPG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 4 at 12:08 PM
americanbankingnews.com logoGalapagos NV (GLPG) Given Daily News Sentiment Rating of 0.03
www.americanbankingnews.com - May 2 at 6:36 PM
americanbankingnews.com logoStifel Nicolaus Reaffirms Hold Rating for Galapagos NV (GLPG)
www.americanbankingnews.com - May 1 at 1:40 PM
streetinsider.com logoGalapagos NV (GLPG): Filgotinib Progressing Nicely - Stifel - StreetInsider.com
www.streetinsider.com - May 1 at 11:56 AM
americanbankingnews.com logoGalapagos NV (GLPG) Given News Impact Rating of 0.07
www.americanbankingnews.com - April 29 at 4:18 PM
finanznachrichten.de logoGalapagos NV: Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
www.finanznachrichten.de - April 29 at 9:34 AM
finance.yahoo.com logoGalapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
finance.yahoo.com - April 29 at 9:33 AM
finance.yahoo.com logoETFs with exposure to Galapagos NV : April 28, 2017
finance.yahoo.com - April 28 at 6:30 PM
americanbankingnews.com logoJanney Montgomery Scott Downgrades Galapagos NV (GLPG) to Sell
www.americanbankingnews.com - April 28 at 7:16 AM
finance.yahoo.com logoGalapagos reports first quarter 2017 results
finance.yahoo.com - April 27 at 6:03 PM
streetinsider.com logoGalapagos NV (GLPG) Reports Phase 2 Proof-of-Concept Study with Filgotinib in CLE - StreetInsider.com
www.streetinsider.com - April 27 at 8:03 AM
streetinsider.com logoGalapagos NV (GLPG) Reports Phase 2 Proof-of-Concept Study with Filgotinib in CLE
www.streetinsider.com - April 26 at 7:56 PM
americanbankingnews.com logo$31.81 Million in Sales Expected for Galapagos NV (GLPG) This Quarter
www.americanbankingnews.com - April 26 at 10:52 AM
americanbankingnews.com logoGalapagos NV (GLPG) Earns Daily Media Sentiment Rating of 0.15
www.americanbankingnews.com - April 25 at 8:56 PM
finance.yahoo.com logoGalapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus
finance.yahoo.com - April 25 at 5:01 PM
americanbankingnews.com logoGalapagos NV (GLPG) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 24 at 10:18 PM
americanbankingnews.com logoJanney Montgomery Scott Lowers Galapagos NV (GLPG) to Sell
www.americanbankingnews.com - April 24 at 9:07 PM
americanbankingnews.com logo Brokerages Anticipate Galapagos NV (GLPG) to Announce -$0.50 Earnings Per Share
www.americanbankingnews.com - April 24 at 7:33 PM
globenewswire.com logoGalapagos announces capital increase - GlobeNewswire (press release)
globenewswire.com - April 22 at 8:35 AM
finanznachrichten.de logoGalapagos NV: Galapagos announces capital increase
www.finanznachrichten.de - April 21 at 10:26 PM
finance.yahoo.com logoGalapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million
finance.yahoo.com - April 21 at 5:26 PM
feeds.benzinga.com logoGalapagos announces capital increase
feeds.benzinga.com - April 21 at 4:22 PM
streetinsider.com logoGalapagos NV (GLPG) Prices 3.75M Offering at $90/Share
www.streetinsider.com - April 19 at 11:51 AM
nasdaq.com logoGalapagos Raises $338 Mln Gross Proceeds In 3.75 Mln Shares US Public Offering
www.nasdaq.com - April 18 at 11:27 AM
streetinsider.com logoGalapagos NV (GLPG) Announces $275M Offering of ADSs
www.streetinsider.com - April 18 at 11:27 AM
finanznachrichten.de logoGalapagos NV: Galapagos announces launch of proposed public offering
www.finanznachrichten.de - April 17 at 4:56 PM
finance.yahoo.com logoGalapagos announces launch of proposed public offering
finance.yahoo.com - April 17 at 4:56 PM
americanbankingnews.com logoGalapagos NV (GLPG) Getting Somewhat Negative Media Coverage, Report Finds
www.americanbankingnews.com - April 17 at 3:20 PM
americanbankingnews.com logoGalapagos NV (GLPG) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 11 at 11:34 AM
streetinsider.com logoGalapagos NV (GLPG) Doses First Patient in EQUATOR Phase 2 study; Triggers $10M Payment from Gilead - StreetInsider.com
www.streetinsider.com - April 7 at 5:22 PM
streetinsider.com logoGalapagos NV (GLPG) Reports Warrant Exercises - StreetInsider.com
www.streetinsider.com - April 7 at 5:22 PM
finanznachrichten.de logoGalapagos NV: Galapagos doses first psoriatic arthritis patient with filgotinib
www.finanznachrichten.de - April 7 at 10:03 AM
streetinsider.com logoGalapagos NV (GLPG) Doses First Patient in EQUATOR Phase 2 study; Triggers $10M Payment from Gilead
www.streetinsider.com - April 7 at 10:03 AM
finance.yahoo.com logoGalapagos increases share capital through warrant exercises
finance.yahoo.com - April 7 at 10:03 AM
feeds.benzinga.com logoGalapagos doses first psoriatic arthritis patient with filgotinib
feeds.benzinga.com - April 5 at 4:22 PM
finance.yahoo.com logoGALAPAGOS NV Financials
finance.yahoo.com - March 29 at 5:56 PM
americanbankingnews.com logoGalapagos NV (GLPG) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 28 at 9:53 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial
finance.yahoo.com - March 24 at 5:35 PM
nasdaq.com logoHealth Care Sector Update for 03/22/2017: GLPG,ABBV,MBRX,VTL ... - Nasdaq
www.nasdaq.com - March 24 at 8:47 AM
streetinsider.com logoGalapagos NV (GLPG) Announces Initiation of Phase 1 Study for Cystic Fibrosis Potentiator GLPG3067; Triggers $7.5 ... - StreetInsider.com
www.streetinsider.com - March 24 at 8:47 AM

Social

Chart

Galapagos NV (GLPG) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff